Trial record 2 of 24 for:    "Conn's syndrome"

Metabolic Syndrome and Insulin Resistance in Primary Aldosteronism

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2007 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00173082
First received: September 12, 2005
Last updated: November 28, 2007
Last verified: November 2007
  Purpose

Primary aldosteronism (PA) is occasionally associated with impaired glucose tolerance. Glucose intolerance, in general metabolic syndrome is caused by suppression of insulin release from the pancreas and suppression of insulin sensitivity of the target tissues. Several studies have suggested that impaired glucose tolerance in primary aldosteronism is due to an inability of the beta cells to release insulin by potassium depletion. It was suggested glucose intolerance in PA is caused by the suppression of insulin release related to hypopotassemia and compensatory increase of insulin sensitivity is observed in PA. The increased insulin secretory capacity associated with correction of negative potassium balance may account for the increase in plasma leptin after curing primary aldosteronism. The conclusion with respect to the possible causal relationship between diabetes mellitus (DM) and PA, however, can be obtained after the evaluation of the effect of surgical /pharmacological treatment of PA.


Condition Intervention
Primary Aldosteronism
Procedure: Glucose tolerance test

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Metabolic Syndrome and Insulin Resistance in Primary Aldosteronism

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 100
Study Start Date: June 2005
Estimated Study Completion Date: July 2008
Detailed Description:

Primary aldosteronism (PA) is occasionally associated with impaired glucose tolerance. Glucose intolerance, in general metabolic syndrome is caused by suppression of insulin release from the pancreas and suppression of insulin sensitivity of the target tissues. Several studies have suggested that impaired glucose tolerance in primary aldosteronism is due to an inability of the beta cells to release insulin by potassium depletion. It was suggested glucose intolerance in PA is caused by the suppression of insulin release related to hypopotassemia and compensatory increase of insulin sensitivity is observed in PA. The increased insulin secretory capacity associated with correction of negative potassium balance may account for the increase in plasma leptin after curing primary aldosteronism. The conclusion with respect to the possible causal relationship between DM and PA, however, can be obtained after the evaluation of the effect of surgical /pharmacological treatment of PA. From July 2005 to July 2008, patients with primary aldosteronism, hospitalized for a comprehensive study of the subtypes of primary aldosteronism before operation will receive informed consent about the insulin sensitivity test. In the present study, we measured insulin sensitivity via the ability to release insulin by the 75 g oral glucose tolerance test (OGTT) in PA to clarify the mechanisms of glucose intolerance in PA. Seventy-five gram OGTT was performed in PA before and after adrenalectomy. Within one minute, 75 g of glucose dissolved in 200 cc water was ingested. Venous blood samples were drawn at 0, 60, 120 minutes for determination of plasma glucose and plasma insulin levels. Serum potassium levels were measures at 0 minutes. Furthermore, the adipokines, HOMA, QUICKI, leptin, adiponectin, homocystine, C-reactive protein, proinflammatory cytokine and adhesion molecules were also measured.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age more than 18 years old
  • Aldosteronism patients

Exclusion Criteria:

  • Patients with pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00173082

Contacts
Contact: Vin-cent Wu, MD +886-2-23562082 kdw@ha.mc.ntu.edu.tw

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Vincent Wu, MD    +886-2-23562082    walt-wu@yahoo.com.tw   
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Study Chair: Kwan-Dun Wu, MD, PhD National Taiwan University Hospital
Study Director: Vin-cent Wu, MD National Taiwan University Hospital
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00173082     History of Changes
Other Study ID Numbers: 9461700402
Study First Received: September 12, 2005
Last Updated: November 28, 2007
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
primary aldosteronism
Insulin resistance
Metabolic syndrome
OGTT

Additional relevant MeSH terms:
Hyperaldosteronism
Insulin Resistance
Metabolic Syndrome X
Adrenocortical Hyperfunction
Adrenal Gland Diseases
Endocrine System Diseases
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 31, 2014